Positive regulation of hepatitis E virus replication by microRNA-122.

Bangari Haldipur,Prudhvi Lal Bhukya,Vidya Arankalle,Kavita Lole
DOI: https://doi.org/10.1128/JVI.01999-17
IF: 6.549
2019-10-03
Journal of Virology
Abstract:Molecular mechanisms of liver pathology and clinical disease in HEV infection remain unclear. MicroRNAs are known to modulate viral pathogenesis either by directly altering viral gene expression or by enhancing cellular antiviral responses. Given the importance of microRNA-122 (miR-122) in liver pathobiology, we investigated possible role of miR-122 in HEV infection. In silico predictions using genotype 1, 2, 3 and 4 HEV sequences showed that majority of genomes (203/222) harbor at least one miR-122/miR-122* target site. Interestingly, HEV-1 genomes showed a highly conserved (97%) miR-122 target site in RdRp encoding region (RdRp c ). We analyzed significance of miR-122 target sites in HEV-1/3 genomes by using replicon based cell culture system. HEV infection did not change basal levels of miR-122 in hepatoma cells. However, transfection of these cells with miR-122 mimics enhanced HEV-1/3 replication and depletion of miR-122 with inhibitors lead to suppression of HEV-1/3 replication. Mutant HEV-1 replicons with altered target RdRp c sequence (CACTCC) showed a drastic decrease in virus replication. While, introduction of alternative miR-122 target sites in mutant replicons rescued viral replication. There was enrichment of HEV-1 RNA and miR-122 molecules in RNA-induced silencing complexes in HEV infected cells. Furthermore, pulldown of miR-122 molecules from HEV-infected cells resulted in pulldown of HEV genomic RNA along with miR-122 molecules. These observations indicate that miR-122 facilitates HEV-1 replication probably via direct interaction with target site in viral genome. The positive role of miR-122 in viral replication presents novel opportunities for antiviral therapy and management of Hepatitis E. IMPORTANCE Hepatitis E is a problem of both developing and developed countries. HEV infection in most patients follows a self-limited course; however, 20-30% mortality is seen in infected pregnant women. HEV super-infections in patients with chronic hepatitis B or hepatitis C virus infections are associated with adverse clinical outcomes and both these conditions warrant therapy. Chronic HEV infections in immunocompromised transplant recipients are known to rapidly progress into cirrhosis. Currently, off-label use of ribavirin (RBV) and PEG-IFN as antiviral therapy have shown promising results in both acute and chronic hepatitis E patients, however teratogenecity of RBV limits its use during pregnancy, while, IFN-α increases risk of transplant rejections. Experimental data with genotype 1 virus in the current study shows that miR-122 facilitates HEV replication. These observations present novel opportunities for antiviral therapy and management of Hepatitis E.
virology
What problem does this paper attempt to address?